Noven Pharmaceuticals, Inc. Overview
Pro stress-test →Noven Pharmaceuticals is a specialty pharmaceutical company engaged in research, development, manufacture, marketing and sale of prescription pharmaceutical products, with a commitment to advancing patient care through transdermal drug delivery. The company is a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., the world's largest manufacturer of transdermal patches, and serves as Hisamitsu's growth platform for U.S. prescription pharmaceuticals.
Strategic Profile
Pro stress-test →Noven's commercialized products and product development activities are principally focused in the areas of women's health and mental health, including ADHD and schizophrenia. The company maintains state-of-the art, FDA-approved transdermal manufacturing facilities in Miami with capacity to produce several hundred million patches per year. Noven operates with over 300 colleagues at locations in Miami, Florida and Jersey City, New Jersey.
Competitive Landscape
Pro stress-test →Noven competes within a marketplace that includes pharmaceutical giants such as Pfizer, among approximately 23 identified competitors. The company's transdermal-focused positioning differentiates it from broader pharma competitors, particularly in specialty applications (women's health, psychiatry/ADHD). Primary competition comes from established transdermal and oral delivery alternatives in mental health and HRT markets.
Industry Context
Noven Pharmaceuticals, Inc. operates in Specialty Pharmaceuticals / Transdermal Drug Delivery.
Key facts
Founded: 1987 · Headquarters: Miami, Florida · Employees: 300+